RU2018132559A - Связывающие молекулы для max в качестве модуляторов myc и их применения - Google Patents
Связывающие молекулы для max в качестве модуляторов myc и их применения Download PDFInfo
- Publication number
- RU2018132559A RU2018132559A RU2018132559A RU2018132559A RU2018132559A RU 2018132559 A RU2018132559 A RU 2018132559A RU 2018132559 A RU2018132559 A RU 2018132559A RU 2018132559 A RU2018132559 A RU 2018132559A RU 2018132559 A RU2018132559 A RU 2018132559A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- unsubstituted
- heterocyclyl
- heteroaryl
- represents hydrogen
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 62
- 125000001072 heteroaryl group Chemical group 0.000 claims 60
- 125000003118 aryl group Chemical group 0.000 claims 58
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 229910052739 hydrogen Inorganic materials 0.000 claims 53
- 239000001257 hydrogen Substances 0.000 claims 53
- 150000002431 hydrogen Chemical class 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 48
- 125000004452 carbocyclyl group Chemical group 0.000 claims 41
- 125000002252 acyl group Chemical group 0.000 claims 32
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 125000000304 alkynyl group Chemical group 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 13
- 125000006239 protecting group Chemical group 0.000 claims 8
- 125000003003 spiro group Chemical group 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 230000001681 protective effect Effects 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000053227 Themus Species 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004354 sulfur functional group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295996P | 2016-02-16 | 2016-02-16 | |
| US62/295,996 | 2016-02-16 | ||
| PCT/US2017/018162 WO2017143059A1 (en) | 2016-02-16 | 2017-02-16 | Max binders as myc modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018132559A true RU2018132559A (ru) | 2020-03-17 |
Family
ID=58191662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018132559A RU2018132559A (ru) | 2016-02-16 | 2017-02-16 | Связывающие молекулы для max в качестве модуляторов myc и их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10106555B2 (OSRAM) |
| EP (1) | EP3416950A1 (OSRAM) |
| JP (1) | JP2019505548A (OSRAM) |
| KR (1) | KR20180107261A (OSRAM) |
| CN (1) | CN109071456A (OSRAM) |
| AU (1) | AU2017221422A1 (OSRAM) |
| BR (1) | BR112018016133A2 (OSRAM) |
| CA (1) | CA3012846A1 (OSRAM) |
| MX (1) | MX2018009913A (OSRAM) |
| RU (1) | RU2018132559A (OSRAM) |
| WO (1) | WO2017143059A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018016133A2 (pt) | 2016-02-16 | 2019-01-02 | Massachusetts Inst Technology | aglutinantes de max como moduladores de myc e usos dos mesmos |
| CA3106118A1 (en) * | 2018-07-09 | 2020-01-16 | The Scripps Research Institute | Improved compounds for myc inhibition |
| US20230115837A1 (en) * | 2019-11-08 | 2023-04-13 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| CN111274691A (zh) * | 2020-01-16 | 2020-06-12 | 西安交通大学 | 一种分析预测max相材料可形成能力的方法 |
| JP2023519892A (ja) | 2020-03-27 | 2023-05-15 | ランドス バイオファーマ インコーポレイテッド | Ｐｌｘｄｃ２リガンド |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| WO2000018746A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| AU6325799A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| WO2003027081A2 (en) | 2001-09-14 | 2003-04-03 | Novo Nordisk A/S | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
| US20050042674A9 (en) | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| WO2004024061A2 (en) | 2002-04-30 | 2004-03-25 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| CA2538759C (en) | 2003-09-12 | 2015-11-03 | Elixir Pharmaceuticals, Inc. | Substituted heterocyclic compounds as sirtuin inhitibitors |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| WO2005033090A1 (ja) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | 芳香族化合物 |
| WO2006005683A1 (en) | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| PL1746097T3 (pl) | 2005-07-20 | 2010-06-30 | Aventis Pharma Sa | Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| AU2007257959A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20100292188A1 (en) | 2008-01-24 | 2010-11-18 | Ucb Pharma S.A. | Compounds Comprising A Cyclobutoxy Group |
| US8133695B2 (en) | 2008-02-28 | 2012-03-13 | Life Technologies Corporation | Fluorescence polarization hERG assay |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| WO2010058402A1 (en) | 2008-11-20 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Novel anti-biofilm agents |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| EP2504344A4 (en) | 2009-11-24 | 2013-06-05 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
| US8575177B2 (en) | 2009-12-04 | 2013-11-05 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
| WO2012033149A1 (ja) | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| JPWO2012153780A1 (ja) | 2011-05-11 | 2014-07-31 | 出光興産株式会社 | 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子 |
| JPWO2013038650A1 (ja) | 2011-09-13 | 2015-03-23 | 出光興産株式会社 | 縮合複素芳香族誘導体、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子 |
| JP6653573B2 (ja) | 2012-05-22 | 2020-02-26 | トラスティーズ・オブ・ダートマウス・カレッジ | シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法 |
| BR112015012454B1 (pt) * | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
| EP2985278B1 (en) | 2013-02-28 | 2020-01-22 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound and pest control applications thereof |
| US8901164B2 (en) * | 2013-03-07 | 2014-12-02 | University Of Maryland, Baltimore | Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold |
| US9695179B2 (en) | 2013-03-14 | 2017-07-04 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| US9242944B2 (en) | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| KR20160122123A (ko) | 2013-12-11 | 2016-10-21 | 더 스크립스 리서치 인스티튜트 | 저분자 c-myc 억제제들 |
| JP2017537940A (ja) | 2014-12-10 | 2017-12-21 | マサチューセッツ インスティテュート オブ テクノロジー | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 |
| BR112018016133A2 (pt) | 2016-02-16 | 2019-01-02 | Massachusetts Inst Technology | aglutinantes de max como moduladores de myc e usos dos mesmos |
-
2017
- 2017-02-16 BR BR112018016133A patent/BR112018016133A2/pt not_active Application Discontinuation
- 2017-02-16 JP JP2018543356A patent/JP2019505548A/ja active Pending
- 2017-02-16 MX MX2018009913A patent/MX2018009913A/es unknown
- 2017-02-16 CN CN201780011783.5A patent/CN109071456A/zh active Pending
- 2017-02-16 KR KR1020187026354A patent/KR20180107261A/ko not_active Withdrawn
- 2017-02-16 AU AU2017221422A patent/AU2017221422A1/en not_active Abandoned
- 2017-02-16 RU RU2018132559A patent/RU2018132559A/ru not_active Application Discontinuation
- 2017-02-16 US US15/435,003 patent/US10106555B2/en active Active
- 2017-02-16 CA CA3012846A patent/CA3012846A1/en not_active Abandoned
- 2017-02-16 EP EP17708095.9A patent/EP3416950A1/en not_active Withdrawn
- 2017-02-16 WO PCT/US2017/018162 patent/WO2017143059A1/en not_active Ceased
-
2018
- 2018-10-22 US US16/167,238 patent/US10865213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018009913A (es) | 2018-11-29 |
| KR20180107261A (ko) | 2018-10-01 |
| US10865213B2 (en) | 2020-12-15 |
| US10106555B2 (en) | 2018-10-23 |
| US20190144466A1 (en) | 2019-05-16 |
| US20170233405A1 (en) | 2017-08-17 |
| EP3416950A1 (en) | 2018-12-26 |
| CN109071456A (zh) | 2018-12-21 |
| WO2017143059A1 (en) | 2017-08-24 |
| AU2017221422A1 (en) | 2018-08-16 |
| CA3012846A1 (en) | 2017-08-24 |
| BR112018016133A2 (pt) | 2019-01-02 |
| JP2019505548A (ja) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018132559A (ru) | Связывающие молекулы для max в качестве модуляторов myc и их применения | |
| JP2016531113A5 (OSRAM) | ||
| JP2017510610A5 (OSRAM) | ||
| JP2017537940A5 (OSRAM) | ||
| JP2017533922A5 (OSRAM) | ||
| JP2017527532A5 (OSRAM) | ||
| JP2014521653A5 (OSRAM) | ||
| JP2013512903A5 (OSRAM) | ||
| JP2019514884A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| ES2949852T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
| JP2015532295A5 (OSRAM) | ||
| JP2016506959A5 (OSRAM) | ||
| JP2014508804A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2013518050A5 (OSRAM) | ||
| JP2014510774A5 (OSRAM) | ||
| JP2014507455A5 (OSRAM) | ||
| JP2015522650A5 (OSRAM) | ||
| ES2875737T3 (es) | Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos | |
| JP2018507166A5 (OSRAM) | ||
| RU2017118792A (ru) | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение | |
| JP2016531126A5 (OSRAM) | ||
| JPWO2023099623A5 (OSRAM) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant | ||
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200217 |